Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13979120 | 0.87 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2GAAPKMLMNA | |
| SCHEMBL4813897 | 0.86 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2GAAPKMLMNA | |
| SCHEMBL18775352 | 0.84 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2GAALMNAMAPT | |
| SCHEMBL11441525 | 0.80 | SMN1; SMN2 (0.71) | ALDH1A1SMN1; SMN2HPGDKMT2APOLB | |
| SCHEMBL15023508 | 0.79 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2PKMLMNAMAPT | |
| SCHEMBL3845087 | 0.79 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2GAAPKMLMNA | |
| SCHEMBL31019312 | 0.78 | GAA (0.54) | ALDH1A1SMN1; SMN2GAAPKMLMNA | |
| Hydrochloric Acid SCHEMBL8841049 | 0.77 | SMN1; SMN2 (0.56) | ALDH1A1SMN1; SMN2GAAPKMMAPT | |
| SCHEMBL6277688 | 0.77 | SMN1; SMN2 (0.56) | ALDH1A1SMN1; SMN2GAAPKMMAPT | |
| SCHEMBL3452433 | 0.77 | POLB (0.68) | SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170115259-A1 | HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR ANALYZING IMAGING AGENT, PRECURSOR OF IMAGING AGENT, OR INTERMEDIATE OF IMAGING AGENT | Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C. (TW) | 2017-04-27 | — | — | US | claimed |
| US-20250319213-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | ABX ADVANCED BIOCHEMICAL COMPOUNDS – BIOMEDIZINISCHE FORSCHUNGSREAGENZIEN GMBH (DE) | 2025-10-16 | — | — | US | disclosed |
| EP-4529473-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | ABX Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH (DE) | 2025-04-02 | — | — | EP | disclosed |
| WO-2023227535-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH (DE) | 2023-11-30 | — | — | WO | disclosed |
| EP-4282438-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | ABX Advanced Biochemical Compounds GmbH (DE) | 2023-11-29 | — | — | EP | disclosed |
| US-20170115259-A1 | HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR ANALYZING IMAGING AGENT, PRECURSOR OF IMAGING AGENT, OR INTERMEDIATE OF IMAGING AGENT | Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C. (TW) | 2017-04-27 | — | — | US | disclosed |
| US-20170115259-A1 | HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR ANALYZING IMAGING AGENT, PRECURSOR OF IMAGING AGENT, OR INTERMEDIATE OF IMAGING AGENT | Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C. (TW) | 2017-04-27 | — | — | US | disclosed |
| EP-2605801-A1 | IMAGING TUBERCULOSIS WITH PYRAZINAMIDE CONTRAST AGENTS | GE Healthcare UK Limited (GB) | 2013-06-26 | — | — | EP | disclosed |
| US-20130149249-A1 | IMAGING TUBERCULOSIS WITH PYRAZINAMIDE CONTRAST AGENTS | GE HEALTHCARE LIMITED (GB) | 2013-06-13 | — | — | US | disclosed |
| US-20130149249-A1 | IMAGING TUBERCULOSIS WITH PYRAZINAMIDE CONTRAST AGENTS | GE HEALTHCARE LIMITED (GB) | 2013-06-13 | — | — | US | disclosed |
| WO-2012022812-A1 | IMAGING TUBERCULOSIS WITH PYRAZINAMIDE CONTRAST AGENTS | GE HEALTHCARE LIMITED (GB) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012022812-A1 | IMAGING TUBERCULOSIS WITH PYRAZINAMIDE CONTRAST AGENTS | GE HEALTHCARE LIMITED (GB) | 2012-02-23 | — | — | WO | disclosed |
| CN-101096358-B | Method for synthesizing nucleus medical imaging agent ligand | BEIJING NORMAL UNIVERSITY (CN) | 2011-12-28 | — | — | CN | disclosed |
| US-7378079-B2 | Agents for imaging and diagnostic methods using them | NST NEUROSURVIVAL TECHNOLOGIES LTD. (IL) | 2008-05-27 | — | — | US | disclosed |
| US-7378079-B2 | Agents for imaging and diagnostic methods using them | NST NEUROSURVIVAL TECHNOLOGIES LTD. (IL) | 2008-05-27 | — | — | US | disclosed |
| US-7378079-B2 | Agents for imaging and diagnostic methods using them | NST NEUROSURVIVAL TECHNOLOGIES LTD. (IL) | 2008-05-27 | — | — | US | disclosed |
| CN-101096358-A | Method for synthesizing nucleus medical imaging agent ligand | UNIV BEIJING NORMAL (CN) | 2008-01-02 | — | — | CN | disclosed |
| US-20050276750-A1 | Agents for imaging and diagnostic methods using them | APOSENSE LTD. (IL) | 2005-12-15 | — | — | US | disclosed |
| EP-1546092-A2 | AGENTS FOR IMAGING AND DIAGNOSTIC METHODS USING THEM | Nst Neurosurvival Technologies Ltd. (IL) | 2005-06-29 | — | — | EP | disclosed |
| WO-2003101948-A2 | AGENTS FOR IMAGING AND DIAGNOSTIC METHODS USING THEM | NST NEUROSURVIVAL TECHNOLOGIES LTD. (IL) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130149249-A1 | IMAGING TUBERCULOSIS WITH PYRAZINAMIDE CONTRAST AGENTS | CTPS1, CTPS2, MPI | ALDH1A1 1652/4885SMN1; SMN2 4820/4885GAA 2465/4885 |
| US-20050276750-A1 | Agents for imaging and diagnostic methods using them | ANXA4, ANXA3, NME4 | ALDH1A1 4325/4885SMN1; SMN2 2097/4885GAA 1769/4885 |
| US-20250319213-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | MARS1, MARS2, BCAT1 | ALDH1A1 3187/4885SMN1; SMN2 3434/4885GAA 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.